SCHEMBL13403147

SCHEMBL13403147

CC(C)(C)C(=O)/C=C/c1c[nH]cn1

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.36
KMT2A Q03164 3/20 0.36
NPC1 O15118 2/20 0.36
MEN1 O00255 2/20 0.36
LMNA P02545 1/20 0.36
RAB9A P51151 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
MAPT P10636 3/20 0.31
GAA P10253 3/20 0.31
KDM4E B2RXH2 2/20 0.31
TSHR P16473 1/20 0.31
HPGD P15428 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
HSD17B10 Q99714 1/20 0.31
HTT P42858 1/20 0.31
THRB P10828 1/20 0.30
NPSR1 Q6W5P4 1/20 0.30
TDP1 Q9NUW8 1/20 0.30
MAPK1 P28482 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2632247 0.80 MAPT (0.41) ALDH1A1KMT2AMEN1LMNAMAPT
SCHEMBL2999621 0.79 EGFR (0.47) ALDH1A1KMT2ANPC1LMNARAB9A
SCHEMBL18982604 0.79 LMNA (0.34) KMT2AMEN1LMNAHTT
SCHEMBL18982605 0.79 LMNA (0.34) KMT2AMEN1LMNAHTT
Cis-Urocanic Acid SCHEMBL1755678 0.78 KDM4E (0.43) ALDH1A1KMT2AMEN1LMNARAB9A
Cis-Urocanic Acid SCHEMBL15418 0.78 KDM4E (0.43) ALDH1A1KMT2AMEN1LMNARAB9A
Cis-Urocanic Acid SCHEMBL19031717 0.78 KDM4E (0.43) ALDH1A1KMT2AMEN1LMNARAB9A
Cis-Urocanic Acid SCHEMBL15417 0.78 KDM4E (0.43) ALDH1A1KMT2AMEN1LMNARAB9A
Cis-Urocanic Acid SCHEMBL1311341 0.78 KDM4E (0.43) ALDH1A1KMT2AMEN1LMNARAB9A
Cis-Urocanic Acid SCHEMBL7715147 0.77 KDM4E (0.42) ALDH1A1KMT2AMEN1LMNARAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9822134-B2 System for delivering therapeutic agents into living cells and cells nuclei SABAG-RFA LTD. (IL) 2017-11-21 US disclosed
US-9822134-B2 System for delivering therapeutic agents into living cells and cells nuclei SABAG-RFA LTD. (IL) 2017-11-21 US disclosed
US-9556210-B2 System for delivering therapeutic agents into living cells and cells nuclei SABAG-RFA LTD. (IL) 2017-01-31 US disclosed
US-9556210-B2 System for delivering therapeutic agents into living cells and cells nuclei SABAG-RFA LTD. (IL) 2017-01-31 US disclosed
US-20160176903-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI SABAG-RFA LTD. (IL) 2016-06-23 US disclosed
US-20160039850-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI SABAG-RFA LTD. (IL) 2016-02-11 US disclosed
US-9156865-B2 System for delivering therapeutic agents into living cells and cells nuclei DELIVERSIR LTD (IL) 2015-10-13 US disclosed
US-8680062-B2 System for delivering therapeutic agents into living cells and cells nuclei Deliversir Ltd. (IL) 2014-03-25 US disclosed
US-20130137755-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI SEGEV LABORATORIES LIMITED (IL) 2013-05-30 US disclosed
US-8293209-B2 System for delivering therapeutic agents into living cells and cells nuclei SEGEV LABORATORIES LIMITED (IL) 2012-10-23 US disclosed
US-20100092386-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI SABAG-RFA LTD. (IL) 2010-04-15 US disclosed
US-20080004234-A1 System for delivering therapeutic agents into living cells and cells nuclei SEGEV LABORATORIES LIMITED (IL) 2008-01-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160039850-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI NFATC1, KPNA2, KPNA6 ALDH1A1 4566/4885KMT2A 3225/4885NPC1 108/4885
US-20100092386-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI NFATC1, KPNA2, KPNA6 ALDH1A1 4566/4885KMT2A 3225/4885NPC1 108/4885
US-20130137755-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI NFATC1, KPNA2, KPNA6 ALDH1A1 4566/4885KMT2A 3225/4885NPC1 108/4885
US-20160176903-A1 SYSTEM FOR DELIVERING THERAPEUTIC AGENTS INTO LIVING CELLS AND CELLS NUCLEI NFATC1, KPNA2, KPNA6 ALDH1A1 4566/4885KMT2A 3225/4885NPC1 108/4885
US-20080004234-A1 System for delivering therapeutic agents into living cells and cells nuclei RCC1, NUMA1, ACIN1 ALDH1A1 3923/4885KMT2A 4420/4885NPC1 242/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.